

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Dupilumab for treating moderate to severe prurigo nodularis [ID4054]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Issues raised during consultation:

1. One stakeholder stated that in previous appraisals for dermatology indications, the committee noted that it is possible that the tools for assessing the severity and response to treatment may not be sensitive enough in people with darker skin pigmentation.

Issues discussed during the scoping workshop:

2. A study in the United States reported a higher prevalence of prurigo nodularis in people of African and African Caribbean family background.
3. Prurigo nodularis is more prevalent in people of south and east Asian family background in the UK who are more likely to have severe eczema and prurigo nodularis.
4. Prurigo nodularis presents more frequently in women.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The above issues will be considered by committee during the appraisal.

Particular consideration should be given to differences in prevalence by ethnicity in UK clinical practice and whether these populations suffer worse health outcomes and barriers to treatment.

Any adjustments by clinicians to account for differences in skin pigmentation will be explored with clinical experts during the appraisal process. However, experts at the scoping workshop suggested that the tools used to assess severity and response do not assess lesion redness so would not be impacted by skin pigmentation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

None required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name):Richard Diaz

Date: 23/11/2022